British Society for Haematology. Listening. Learning. Leading British Society for Haematology. Listening. Learning. Leading
05 June 2019

Spanish researchers have identified a promising new target for the treatment of B-cell lymphomas.

Researchers led by Dr Miguel Gallardo at the Spanish National Cancer Research Centre, Madrid, Spain, examined samples from patients with diffuse large B-cell lymphoma. They found that high levels of a protein called hnRNP K were associated with “dismal” long-term survival.

They subsequently discovered in mice that overproducing hnRNP K selectively in B cells can trigger the development of lymphoma.

Previous work had shown that this protein regulates many cellular processes, and both its over- and under-production are involved in the development of various cancers. This new work confirms the tumour-promoting function of hnRNP K for B-cell lymphomas, the researchers say.

The researchers identified that high levels of hnRNP K in B cells led to the overproduction of c-Myc, a known driver of B-cell lymphoma. However, hnRNP K-positive cells were also sensitive to inhibitors which block the BET-bromodomain, which points to a novel avenue for treatment of some B-cell lymphomas.

Dr Gallardo said: “Overexpression of hnRNP K is often associated with poor recovery and low survival rates. This was confirmed by findings that overexpression of hnRNP K in transgenic mice resulted in development of lymphoma and reduced survival.”

The study was published in the Journal of the National Cancer Institute.

The authors write: “We and others have previously shown that reduced hnRNP K expression down-modulates tumour suppressive programs. However, over-expression of hnRNP K is the more commonly observed clinical phenomenon, yet its functional consequences and clinical significance remain unknown.

“Our findings indicate that hnRNP K is a bona fide oncogene when overexpressed and represents a novel mechanism for c-Myc activation in the absence of MYC lesions.”

The team believe this discovery may lead to new methods for assessing patients and to the development of novel treatments.


Source: Gallardo, M, Malaney, P, Aitken, M.J.L., Zhang, X., Link, T.M., Shah, V., Alybayev, S., Wu, M.H., Pageon, L.R., Ma, H., Jacamo, R., Yu, L., Xu-Monette, Z.Y., Steinman, H., Lee, H.J., Sarbassov, D., Rapado, I., Barton, M.C., Martinez-Lopez, J., Bueso-Ramos, C., Young, K.H., Post, S.M. (2019) “Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas”, Journal of the National Cancer Institute, available from doi: 10.1093/jnci/djz078

 

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/